F Simon

Summary

Country: France

Publications

  1. ncbi Identification of a new human immunodeficiency virus type 1 distinct from group M and group O
    F Simon
    Laboratoire de Virologie, Hopital Bichat, Paris, France
    Nat Med 4:1032-7. 1998
  2. pmc Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses
    D Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    J Virol 71:8893-8. 1997
  3. pmc Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR
    F Damond
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    J Clin Microbiol 39:4264-8. 2001
  4. doi HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro
    B Roquebert
    AP HP, Groupe Hospitalier Bichat Claude Bernard, Laboratoire de Virologie, Paris F 75018, France
    J Antimicrob Chemother 62:914-20. 2008
  5. ncbi T cell changes after combined nucleoside analogue therapy in HIV primary infection
    G Carcelain
    Laboratoire d Immunologie Cellulaire, CNRS UMR 7527, Hopital Pitie Salpetriere, Paris, France
    AIDS 13:1077-81. 1999
  6. ncbi Lymphoma and Epstein-Barr virus DNA in blood during interleukin-2 therapy in antiretroviral-naïve HIV-1-infected patients: a substudy of the ANRS 119 trial
    V de Lastours
    Department of Infectious Diseases, Saint Louis Hospital, Paris, France University Paris Diderot, Sorbonne Paris Cité, Paris, France
    HIV Med 15:23-9. 2014
  7. doi Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial
    Nathalie de Castro
    Department of Infectious Diseases, Assistance Publique Hopitaux de Paris, Saint Louis Hospital and University of Paris VII Denis Diderot, Paris, France
    Clin Infect Dis 49:1259-67. 2009
  8. doi Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication
    C Delaugerre
    Virology Department, Saint Louis Hospital APHP, INSERM U941 Paris 7 Diderot University, Paris, France
    HIV Med 13:517-25. 2012
  9. ncbi [Classification of retroviruses]
    F Brun-Vezinet
    Laboratoire de Virologie, hôpital Claude Bernard Bichat, Paris
    Rev Prat 40:2116-9. 1990
  10. ncbi Variability of human immunodeficiency virus type 2 (hiv-2) infecting patients living in france
    F Damond
    Laboratoire de Virologie, , Paris Cedex 18, 75877, France
    Virology 280:19-30. 2001

Detail Information

Publications12

  1. ncbi Identification of a new human immunodeficiency virus type 1 distinct from group M and group O
    F Simon
    Laboratoire de Virologie, Hopital Bichat, Paris, France
    Nat Med 4:1032-7. 1998
    ..YBF30 is as distinct from SIVcpz-gab as it is from HIV-1 group M and can thus be considered as the prototype strain of a new human immunodeficiency virus group...
  2. pmc Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses
    D Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    J Virol 71:8893-8. 1997
    ..The study of HIV-1 group O susceptibility to antiretroviral drugs revealed that the viruses tested had specific phenotypic characteristics contrasting with the group M phenotypic expression...
  3. pmc Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR
    F Damond
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    J Clin Microbiol 39:4264-8. 2001
    ..Proviral load did not correlate with plasma HIV-2 RNA positivity. As HIV-2 is considered to replicate less efficiently than HIV-1, these high proviral loads might be explained by the proliferation of infected cells...
  4. doi HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro
    B Roquebert
    AP HP, Groupe Hospitalier Bichat Claude Bernard, Laboratoire de Virologie, Paris F 75018, France
    J Antimicrob Chemother 62:914-20. 2008
    ..We investigated the in vitro phenotypic susceptibility of HIV-2 isolates from integrase inhibitor (INI)-naive patients to INIs and its relation to HIV-2 integrase gene polymorphism...
  5. ncbi T cell changes after combined nucleoside analogue therapy in HIV primary infection
    G Carcelain
    Laboratoire d Immunologie Cellulaire, CNRS UMR 7527, Hopital Pitie Salpetriere, Paris, France
    AIDS 13:1077-81. 1999
    ..To characterize the immune changes after treatment of acute HIV-1 infection with triple nucleoside analogue therapy...
  6. ncbi Lymphoma and Epstein-Barr virus DNA in blood during interleukin-2 therapy in antiretroviral-naïve HIV-1-infected patients: a substudy of the ANRS 119 trial
    V de Lastours
    Department of Infectious Diseases, Saint Louis Hospital, Paris, France University Paris Diderot, Sorbonne Paris Cité, Paris, France
    HIV Med 15:23-9. 2014
    ..Epstein-Barr virus (EBV) replication is associated with an increased risk of lymphoma in immunocompromised patients. We assessed whether IL-2 had an impact on EBV replication and the development of lymphoma...
  7. doi Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial
    Nathalie de Castro
    Department of Infectious Diseases, Assistance Publique Hopitaux de Paris, Saint Louis Hospital and University of Paris VII Denis Diderot, Paris, France
    Clin Infect Dis 49:1259-67. 2009
    ..We conducted a prospective, randomized, open-label trial to compare the antiviral efficacy and safety of a switch to raltegravir with the efficacy and safety of continuing enfuvirtide...
  8. doi Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication
    C Delaugerre
    Virology Department, Saint Louis Hospital APHP, INSERM U941 Paris 7 Diderot University, Paris, France
    HIV Med 13:517-25. 2012
    ..We examined whether genotyping based on cellular HIV-1 DNA during controlled viraemia identifies resistance mutations detected in plasma HIV-1 RNA during treatment with previous antiretroviral regimens...
  9. ncbi [Classification of retroviruses]
    F Brun-Vezinet
    Laboratoire de Virologie, hôpital Claude Bernard Bichat, Paris
    Rev Prat 40:2116-9. 1990
    ..Several simian virus, called simian immunodeficiency viruses (SIV) and related to HIV-1 and/or HIV-2 have been identified in monkeys and chimpanzees...
  10. ncbi Variability of human immunodeficiency virus type 2 (hiv-2) infecting patients living in france
    F Damond
    Laboratoire de Virologie, , Paris Cedex 18, 75877, France
    Virology 280:19-30. 2001
    ..This could partly explain the double HIV-1 and HIV-2 reactive profiles found in countries where HIV-2 subtype B is prevalent...
  11. pmc V3 serological subtyping of human immunodeficiency virus type 2 infection is not relevant
    J C Plantier
    Laboratoire de Virologie, , , Tours, France
    J Clin Microbiol 39:3803-7. 2001
    ..Comparison of amino acid sequences and serotype reactivities demonstrated the importance of positions 309 and 314, located on either side of the tip of the V3 loop, in antibody binding...
  12. pmc Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors
    F Damond
    Hopital Bichat Claude Bernard, Paris, France
    J Clin Microbiol 43:484-7. 2005
    ..Substitutions selected under treatment were observed at positions corresponding to HIV-1 resistance mutations as well as at positions of currently unknown impact on HIV-1...